Companies /Healthcare

Celldex Therapeutics Inc

NASDAQ: CLDX Biotechnology
$28.83
▲ $0.30 (+1.05%) today
Markets closed · 3:02am ET

CLDX at a Glance

Valuation
Market cap
$2.3B
Profitability
Revenue (TTM)
$158,000
EPS (TTM)
$-4.29
Price
52-week range
$22 – $45
Street target
$64.00

Headquartered in Hampton, NJ Fiscal year ends December NASDAQ: CLDX celldex.com

About Celldex Therapeutics

Celldex Therapeutics is a clinical-stage biotechnology company developing antibody-based therapies for allergic, inflammatory and autoimmune disorders, with a focus on mast cell biology.

Its lead candidate, barzolvolimab (CDX-0159), is a first-in-class humanized monoclonal antibody. It binds a unique part of the KIT receptor to inhibit mast cell activity and survival. The drug has completed Phase 3 topline readouts (EMBARQ-CSU1 and -CSU2) in chronic spontaneous urticaria, and the company plans a BLA submission in 2027. Barzolvolimab is also in a Phase 3 study (EMBARQ-ColdU and -SD) in cold urticaria and symptomatic dermographism, and in a Phase 2 study in atopic dermatitis.

Celldex also runs a bispecific antibody platform anchored on neutralizing soluble stem cell factor (SCF). Its first candidate, CDX-622, targets both SCF and TSLP and is in a Phase 1 proof-of-mechanism study in asthma, with planned expansion into allergic rhinitis and food allergy.

The company currently generates no material revenue; historical revenue came from contracts, grants and services, including work with Rockefeller University. It funds operations from its cash and marketable securities and is building commercial capabilities ahead of a potential barzolvolimab launch. Updated

CLDX Coverage

8:55am ET
Health and Healthcare

30 Big Biotech Events Coming in 2018

Jefferies has compiled a list of over 30 biotech events taking place in 2018 that could result in significant stock moves. Some stocks have the potential to double or even crater, should…

Chris Lange

Frequently Asked Questions

What does Celldex Therapeutics do?

Celldex Therapeutics is a clinical-stage biotechnology company developing antibody-based therapies for allergic, inflammatory and autoimmune disorders, with a focus on mast cell biology. Its lead candidate, barzolvolimab (CDX-0159), is a first-in-class humanized monoclonal antibody.

What is the CLDX stock price target?

The Wall Street consensus 12-month price target for CLDX is $64.00.